Innovative strategies in genitourinary cancer: the role of oncolytic viruses DOI Creative Commons
Jie Zhang,

Kepu Liu,

Zhu Zheng

и другие.

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Окт. 11, 2024

Urinary tumors pose a significant health threat because of their high prevalence and recurrence rates. Despite the availability various treatment options, many patients poorly respond to traditional therapies, highlighting urgent need for alternative approaches. Oncolytic viruses are promising therapeutic agents. These exploit unique characteristics cancer cells specifically target destroy them, thereby triggering potent antitumor immune responses. This review delves into recent advancements future prospects oncolytic viruses, focusing on application in renal, bladder, prostate cancers. By discussing practical implications potential different including cowpox virus, adenovirus, measles coxsackievirus, reovirus, we pave way further exploration refinement this exciting field.

Язык: Английский

Advances in preclinical and clinical studies of oncolytic virus combination therapy DOI Creative Commons
Wenlong Du,

Jintong Na,

Liping Zhong

и другие.

Frontiers in Oncology, Год журнала: 2025, Номер 15

Опубликована: Фев. 7, 2025

Oncolytic viruses represent a distinct class of that selectively infect and destroy tumor cells while sparing normal cells. Despite their potential, oncolytic encounter several challenges as standalone therapies. Consequently, the combination with other therapeutic modalities has emerged prominent research focus. This paper summarizes tumor-killing mechanisms viruses, explores integration radiotherapy, chemotherapy, immune checkpoint inhibitors, CAR-T, CAR-NK therapies, provides an overview related clinical trials. By synthesizing these advancements, this study seeks to offer valuable insights for translation virus

Язык: Английский

Процитировано

1

An updated review of HSV-1 infection-associated diseases and treatment, vaccine development, and vector therapy application DOI Creative Commons
Dan Su,

Han Li-ping,

Chengyu Shi

и другие.

Virulence, Год журнала: 2024, Номер 15(1)

Опубликована: Ноя. 7, 2024

Herpes simplex virus type 1 (HSV-1) is a globally widespread that causes and associates with wide range of diseases, including herpes encephalitis, keratitis, labialis. The interaction between HSV-1 the host involves complex immune response mechanisms, recognition viral invasion, maintenance latent infection, triggering reactivation. Antiviral therapy core treatment for infections. Meanwhile, vaccine development employs different strategies methods, several promising types have emerged, such as live attenuated, protein subunit, nucleic acid vaccines, offering new possibilities prevention infection. Moreover, can be modified into therapeutic vector gene tumour immunotherapy. This review provides an in-depth summary infection-associated innate adaptive responses, disease pathogenesis, current approaches, recent advances in development, applications cancer treatment. Through systematic multiple aspects HSV-1, this study aims to provide comprehensive detailed reference public on prevention, control, HSV-1.

Язык: Английский

Процитировано

8

Current Landscape and Future Directions in Cancer Immunotherapy: Therapies, Trials, and Challenges DOI Open Access
S. A. Tilakaratne Bandara, Sreejith Raveendran

Cancers, Год журнала: 2025, Номер 17(5), С. 821 - 821

Опубликована: Фев. 27, 2025

Cancer remains a leading global health challenge, placing immense burdens on individuals and healthcare systems. Despite advancements in traditional treatments, significant limitations persist, including treatment resistance, severe side effects, disease recurrence. Immunotherapy has emerged as promising alternative, leveraging the immune system to target eliminate tumour cells. However, challenges such immunotherapy patient response variability, need for improved biomarkers limit its widespread success. This review provides comprehensive analysis of current landscape cancer immunotherapy, highlighting both FDA-approved therapies novel approaches clinical development. It explores checkpoint inhibitors, cell gene therapies, monoclonal antibodies, nanotechnology-driven strategies, offering insights into their mechanisms, efficacy, limitations. By integrating emerging research advancements, this underscores continued innovation optimise overcome existing barriers.

Язык: Английский

Процитировано

1

ROS Induced by Aphrocallistes vastus Lectin Enhance Oncolytic Vaccinia Virus Replication and Induce Apoptosis in Hepatocellular Carcinoma Cells DOI Creative Commons
Yanan Zhang, Ying Zhu,

Gaohui Jiang

и другие.

Marine Drugs, Год журнала: 2024, Номер 22(7), С. 307 - 307

Опубликована: Июнь 30, 2024

Oncolytic virotherapy is expected to provide a new treatment strategy for cancer. Aphrocallistes vastus lectin (AVL) Ca2+-dependent receptor containing the conserved domain of C-type and hydrophobic N-terminal region, which can bind bird’s nest glycoprotein D-galactose. Our previous studies suggested that oncolytic vaccinia virus (oncoVV) armed with AVL gene exerted remarkable replication antitumor effects in vitro vivo. In this study, we found oncoVV-AVL may reprogram metabolism hepatocellular carcinoma cells promote ROS, elevated ROS subsequently promoted viral induced apoptosis. This study will theoretical basis application liver

Язык: Английский

Процитировано

4

Immunogenic cell death-based oncolytic virus therapy: a sharp sword of tumor immunotherapy DOI Creative Commons

Jingyu Zhang,

Jiahe Chen, Kezhi Lin

и другие.

European Journal of Pharmacology, Год журнала: 2024, Номер 981, С. 176913 - 176913

Опубликована: Авг. 16, 2024

Язык: Английский

Процитировано

3

Engineered oncolytic virus coated with anti-PD-1 and alendronate for ameliorating intratumoral T cell hypofunction DOI Creative Commons

Yufu Zhu,

Xuefeng Zhang, Jiaqi Jin

и другие.

Experimental Hematology and Oncology, Год журнала: 2025, Номер 14(1)

Опубликована: Фев. 15, 2025

Abstract Background Glioblastoma is a highly aggressive and devastating primary brain tumor that resistant to conventional therapies. Oncolytic viruses represent promising therapeutic approach for glioblastoma by selectively lysing cells eliciting an anti-tumor immune response. However, the clinical efficacy of oncolytic often hindered challenges such as short persistence, host antiviral responses, T cell dysfunction. Methods We have developed novel strategy “dressing” with anti-PD-1 antibodies alendronate (PD-1/Al@OV) prevent premature clearance enhance function, thereby improving immunotherapy outcomes against glioma. Results found in high reactive oxygen species environment tumor, PD-1/Al@OV disassembled release viruses, anti-PD-1, alendronate. The released blocked PD-1/PD-L1 pathway, activating cells; eliminated tumor-associated macrophages, increasing concentration viruses; directly lysed cancer cells, enhancing intratumoral infiltration. Conclusion This effectively improved immunosuppressive microenvironment achieved robust effect. Consequently, this study presents combination therapy improvement microenvironment, offering new prospects application viruses.

Язык: Английский

Процитировано

0

Recent advances in oncolytic virus combined immunotherapy in tumor treatment DOI Creative Commons
Xiaoli Zhou, Shunfeng Hu, Xin Wang

и другие.

Genes & Diseases, Год журнала: 2025, Номер unknown, С. 101599 - 101599

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0

Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies DOI Open Access

Valencia Mc Neil,

Seung Won Lee

Cancers, Год журнала: 2025, Номер 17(9), С. 1408 - 1408

Опубликована: Апрель 23, 2025

A groundbreaking milestone in oncology has been the recognition and targeted elimination of malignant cells through cancer immunotherapy, which harnesses body’s immune system to attack [...]

Язык: Английский

Процитировано

0

Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment of Bladder Cancer. DOI
Jin Guo, S. Xiong, Xinyuan Zhang

и другие.

PubMed, Год журнала: 2025, Номер 18(4)

Опубликована: Март 31, 2025

Background: While Bacillus Calmette-Guérin (BCG) remains the first-line therapy for high-risk bladder cancer, 30-40% of patients develop treatment resistance necessitating radical cystectomy, some are not suitable candidates this procedure. This underscores critical need novel therapeutic approaches. Emerging clinical evidence has increasingly supported potential oncolytic viruses in cancer treatment. Based on foundation, we investigated anti-tumor effects KD01, a type 5 recombinant adenovirus previously developed by our team engineered to express truncated BID (tBID), cancer. Methods: The cytotoxic and efficacy KD01 were systematically evaluated across human cell lines, death pathways RNA sequencing validated. Combination studies with cisplatin employed testing. In final stage, safety instillation was evaluated. Results: induced through multiple mechanisms, including oncolysis, immunogenic death, mitochondrial apoptosis. At higher doses, combined synergistically inhibited proliferation Additionally, amplified damage-associated molecular patterns (DAMPs) release immune activation; combination further enhanced process. Safety evaluations showed favorable tolerance intravesical perfusion KD01. Conclusions: dual action directly killing tumor cells activating immunity its as agent. These findings highlight preclinical informing design trials.

Язык: Английский

Процитировано

0

Biosafety Guidelines for Viral Vector-Based Gene Therapies: A Resource for Healthcare and Pharmacy Professionals DOI
Sumit Ghosh, Jill Blind,

Allison M. Fowler

и другие.

Applied Biosafety, Год журнала: 2025, Номер unknown

Опубликована: Май 15, 2025

Язык: Английский

Процитировано

0